The STING pathway targeting technologies market, featuring a healthy pipeline of therapeutics, is anticipated to be worth over USD 2.8 billion by 2030, predicts Roots Analysis

News provided by

13 Oct, 2020, 15:30 GMT

- STING pathway modulation, using appropriate pharmacological interventions, has emerged as a viable approach to harnessing the immune system for therapeutic purposes; several studies are also exploring its role in COVID-19 pathogenesis, as well

LONDON, Oct. 13, 2020 /PRNewswire/ -- Roots Analysis has announced the addition of "STING Pathway Targeting Therapeutics and Technologies, 2020-2030" report to its list of offerings.

In recent years, the concept of STING pathway targeting therapeutics has generated a lot of enthusiasm within the medical science community. The growing popularity of this therapeutic technique has not only garnered the interest of several medical researchers (reflected in the increasing volume of scientific literature (1,000+ articles published since 2015) on this subject), but also industry stakeholders focused on drug development (evident in the growing number of clinical trials and the grants awarded for STING focused projects in the recent past).

To order this 310+ page report, which features 153 figures and 206 tables, please visit this link.

Key Market Insights

Over time, several technology platforms have been developed to facilitate the design and production of therapeutic modulators of the STING pathway

Majority (83%) of available technologies are currently focused on the development of STING pathway agonists. The technology developer landscape features a mix of small and mid-sized players (92%), most of which are based in North America (70%).

A significant number of STING pathway targeting therapeutics candidates are presently being evaluated across different phases of development

Nearly 20% of pipeline drugs are in the clinical phases of development, while majority are still in the preclinical / discovery stages. Most of the investigational leads are designed to target oncological disorders (78%); this is followed by candidates intended for the treatment of autoimmune disorders (9%) and inflammatory disorders (9%).

Several industry players claim to be engaged in the development of STING pathway targeting therapeutics

The therapy developer landscape is dominated by start-ups (relatively new companies with less than 50 employees), which represent around 60% of the total number of stakeholders in this industry. It is also important to highlight that around 15 big pharma players are actively involved in the development of STING pathway targeting therapeutics.

Close to 365 scientific articles have been published related to STING pathway modulators, since 2019

Close to 80% of the published articles describe various types of therapeutics targeting the cGAS-STING pathway and affiliated technology platforms, with more than 70% reporting insights from experimental studies conducted across the world. Popular journals, in terms of number of STING associated articles published in the given time period, include Frontiers in Immunology and Scientific Reports.

Further, close to USD 2.6 billion in capital investments have been made into various initiatives in this field

A significant proportion of the total capital raised (35%), was from venture capital funding. Over USD 120 million (across ~280 instances) in research-enabling grants, was awarded to projects led by non-industry players engaged in this domain; around 40% of these grants were awarded by National institute of Allergy and Infectious Diseases.

This upcoming field of therapeutics has also witnessed significant partnership activity in the recent past

Most of the reported partnerships were between therapy and technology developers, and research agreements (34%) were the most popular model, in terms of number of deals inked, till date. The maximum number of partnerships were established in 2017, with more than 80% of deals focused on the development of STING agonists.

Presently, the market is driven by revenues from out-licensing STING pathway targeting technology platforms; it is anticipated to grow at a CAGR of around 25%, till 2030

74% of the opportunity is associated with licensing deals involving STING pathway agonist related technologies; according to the findings presented in the report, this trend is unlikely to change in the foreseen future. On the other hand, the market (in terms of technology licensing revenues) for technologies focused on STING antagonists is anticipated to grow at a relatively faster pace (27%), during the period 2020-2030.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

Who are the leading developers of STING pathway targeting therapeutics and affiliated technologies?
What are the most popular STING pathway related technology platforms in the market?
What are the key therapeutic areas for which STING pathway targeting therapeutics are being / have been developed?
What kind of partnership models are commonly adopted by stakeholders engaged in this industry?
What is the trend of capital investment for STING pathway targeting therapeutics and technologies?
How is the current and future opportunity likely to be distributed across key market segments in this domain?

The USD 2.8 billion (by 2030) financial opportunity within the STING pathway targeting technologies market has been analysed across the following segments:

Types of Payment
Upfront Payments
Milestone Payments
Type of STING Modulator
Agonist
Antagonist
Key Therapeutic Area(s)
Oncological Disorders
Inflammatory Disorders
Infectious Diseases
Others
Route of Administration
Intratumoral
Intravenous
Oral
Subcutaneous
Others
Type of Molecule
Non-nucleotide
Cyclic Dinucleotide
Live Biotherapeutics
Oncolytic Peptides
Synthetic Peptides
Others
Key Geographical Regions
North America
Europe
Asia-Pacific

The report features inputs from a number of eminent industry stakeholders, according to whom, the maximum opportunity within this domain is likely to be associated with STING pathway modulators that are being developed for the treatment of oncological disorders. The report features detailed transcripts of discussions held with the following experts:

Glen Barber (Chief Executive Officer, STINGINN)
Kryzsztof Brzozka (Chief Scientific Officer, Ryvu Therapeutics)

The research covers detailed profiles of key players (illustrative list provided below) engaged in the development of STING agonists; each profile features an overview of the developer, details related to its financial performance (if available), product description, recent developments, and an informed future outlook.